BioCina
Adelaide, Australia· Est.
BioCina delivers full‑spectrum, FDA‑approved biologics manufacturing services from Australia, accelerating vaccine and gene‑therapy programs to market.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
BioCina delivers full‑spectrum, FDA‑approved biologics manufacturing services from Australia, accelerating vaccine and gene‑therapy programs to market.
VaccinesGene TherapyOncologyInfectious Diseases
Technology Platform
End‑to‑end biologics CDMO platform covering microbial fermentation, plasmid DNA, mRNA, LNP encapsulation and sterile injectable fill‑and‑finish, all within FDA, EMA and TGA‑approved facilities.
Opportunities
Leverage Australian tax incentives and fast clinical trial start‑up to attract global biotech firms seeking cost‑effective, high‑quality manufacturing for mRNA and gene‑therapy products.
Risk Factors
Regulatory compliance across multiple jurisdictions and capacity constraints could limit ability to scale with rising demand.
Competitive Landscape
Competes with global CDMOs such as Catalent, Lonza and Samsung Biologics; differentiates through FDA‑approved Australian sites, rapid timelines and integrated end‑to‑end services.